Introduction
The glioma-associated oncogene homolog 1 (GLI1) zinc-finger transcription factor is the terminal effector of the Hedgehog pathway having a central role in many physiological processes . GLI1 has been shown to be constitutively activated in breast cancer (Kasper et al., 2009) and associated with poor survival of breast cancer patients (ten Haaf et al., 2009) . The Hedgehog pathway is also important for differentiation and normal development (Echelard et al., 1993; Roelink et al., 1994; Dahmane and Ruiz i Altaba, 1999; Dahmane et al., 2001) and is implicated in tumorigenesis (Dahmane et al., 2001; Rao et al., 2004; Clement et al., 2007; Fiaschi et al., 2009) , vascular development (Lawson et al., 2002; Nagase et al., 2008) and stem cell self-renewal (Liu et al., 2006) . The pathway is highly complex that can be activated following the binding of Sonic hedgehog (Shh) to its receptor patched, PTCH . PTCH is a repressor of a 7-transmembrane receptor smoothened, SMO. Shh binding to PTCH derepresses SMO which, in turn, activates the release of GLI1 transcription factor from SUFU-mediated cytoplasmic sequestration (Kogerman et al., 1999; Kasper et al., 2006) . The released GLI1 translocates into the nucleus and binds to the GLI1-binding element in GLI1-regulated genes, leading to their activation (Kinzler and Vogelstein, 1990) . Both SMO and GLI1 have emerged as therapeutic targets for breast cancer (Mukherjee et al., 2006; Kameda et al., 2009; Yang et al., 2010) . An orally active small molecule SMO inhibitor, GDC-0449, is evaluated in a phase I clinical trial for advanced breast cancer (NCT01071564).
Although the human GLI1 gene was initially identified as an amplified gene from a glioblastoma cell line (Kinzler et al., 1987) , no GLI1 gene amplification has been reported in breast cancer. Somatic mutations are absent in the human GLI1 gene in any cell or tumor type. Until very recently, the human GLI1 gene transcript was found to be alternatively spliced to yield two shorter isoforms, namely, GLI1DN (Shimokawa et al., 2008) and truncated GLI1 (tGLI1) that was identified in our laboratory (Lo et al., 2009 ). GLI1DN contains a large deletion of 128 codons, lacks two functional domains, behaves as a weak GLI1 transcription factor and is expressed in both normal and cancerous cells (Shimokawa et al., 2008) . The novel tGLI1 variant we recently identified contains a small inframe deletion of 123 bp (41 codons) spanning the entire exon 3 and part of exon 4, and retains functional domains and functionality of GLI1, including the ability to undergo nuclear import and to activate GLI1targeted genes, such as PTCH (Lo et al., 2009) . Our functional characterization using glioblastoma models showed that tGLI1 is highly expressed in malignant gliomas but is absent in normal brain and other normal tissues, and that tGLI1 gains the ability to regulate expression of genes that are not regulated by GLI1, such as CD24. We also showed that tGLI1 promotes glioblastoma cell migration and invasion (Lo et al., 2009) .
However, the expression frequency, functional consequences and pathological role of tGLI1 in breast cancer have not been investigated. To address this knowledge gap, we undertook a series of biochemical and genetic studies aiming to define the pathological significance of tGLI1 in breast cancer. Importantly, our findings indicate that tGLI1 behaves as a gain-offunction GLI1 transcription factor in breast cancer and regulates genes that are not targeted by GLI1. This gained property enables tGLI1 to mediate several important phenotypes of more aggressive breast cancer, such as angiogenesis, migration and invasion, and anchorage-independent growth that partially mimics mammary tumorigenesis. The findings of this study establish the first evidence that implicates tGLI1 in the malignant behavior of more aggressive breast cancer.
Results
The novel tGLI1 variant is frequently expressed in human breast cancer cells We found the tGLI1 transcript to be expressed in some of the human breast cancer cell lines and primary specimens we had examined to date (Figure 1a ). In contrast, tGLI1 was undetectable in normal mammary cells and tissues. All PCR products were excised from the agarose gels and subjected to DNA sequencing to confirm tGLI1 versus GLI1 isoforms. The observed expression pattern of tGLI1 is distinctly different from that of GLI1 who is expressed in both cancerous and normal breast cells. As shown in Figure 1b , the encoded tGLI1 protein (146 kD) can be detected in the majority of human breast cancer cell lines and distinguished from the GLI1 protein (150 kD) using prolonged 5.5% SDS-PAGE followed by western blotting (WB) with an antibody that recognizes both isoforms. The expression status of ER, PR and HER2 (Kao et al., 2009 ) and metastatic potential of each cell line are listed at the bottom of Figure 1b . An obvious association between the receptors/metastatic potential and tGLI1 was not observed in the small cohort of breast cancer cell lines examined. tGLI1 is associated with increased vascular endothelial growth factor-A gene expression in human breast cancer and medulloblastoma cells To investigate tGLI1 functionality in breast cancer, we created three isogenic MDA-MB-231 human breast cancer cell lines that stably express control vector (MDA-MB-231-vector), GLI1 (MDA-MB-231-GLI1) and tGLI1 (MDA-MB-231-tGLI1). We chose MDA-MB-231 cells, in part, because of their high degrees of invasiveness and high metastatic potential. As shown in Figure 2a , the levels of transgenes are comparable to those in two natural breast cancer cells, namely, MCF-7 cells that express only the wild-type GLI1 and SK-BR-3 cells that express both isoforms. Shh ligand has been shown to increase vascularity (Kusano et al., 2005; Nagase et al., 2008) ; however, the mechanisms underlying this regulation are still unclear. Since tGLI1 and GLI1 are effectors of the shh pathway and vascular endothelial growth factor-A (VEGF-A) stimulates endothelial cell proliferation leading to angiogenesis, we explored if tGLI1 regulates VEGF-A expression. As shown in Figure 2b , we found that the VEGF-A gene is expressed at a higher level in tGLI1-expressing MDA-MB-231 cells than those with control vector and GLI1. 
The novel tGLI1 variant is frequently expressed in human breast cancer cells. (a) tGLI1 transcript is detected in cell lines and specimens of breast cancer, but not in normal breast cells and tissues. Reverse transcription-polymerase chain reaction (RT-PCR) was conducted to amplify exons 1-4 region of the GLI1/tGLI1 transcripts. All PCR products were extracted and DNA sequenced. (b) tGLI1 protein (146 kD) can be detected in the majority of human breast cancer cell lines and distinguished from the GLI1 protein (150 kD) using prolonged 5.5% SDS-PAGE followed by WB with an antibody that recognizes both isoforms. The expression status of ER, PR and HER2 (Kao et al., 2009 ) and metastatic potential are listed at the bottom of (b).
tGLI1 upregulates VEGF-A and CD24 expression X Cao et al
The observed low level of VEGF-A expression is in line with a previous report showing that MDA-MB-231 cells expressed a low level of VEGF-A (Timoshenko et al., 2006) . The observation of tGLI1-induced VEGF-A expression was further made in human breast cancer HCC38 cells and human medulloblastoma D458 cells ( Figure 2c ). We also observed in breast cancer HCC1937 cells that GLI1 and tGLI1 similarly upregulate VEGF-A expression. These results suggest that VEGF-A gene regulation by tGLI1 and GLI1 is complex and is likely dependent on cellular context. In Figure 2d , we further showed that human breast cancer cell lines with low tGLI1 levels expressed lower levels of VEGF-A than those with high levels of tGLI1, in which levels of tGLI1 were determined previously in Figure 1b . Collectively, we show in Figure 2 that tGLI1 is associated with increased VEGF-A gene expression in human breast cancer and medulloblastoma cells.
tGLI1 has gained the ability to bind to and activate the human VEGF-A gene promoter Using the chromatin immunoprecipitation (ChIP) assays (regular ChIP assays in Figure 3a and quantitative ChIP assay in Figure 3b ), we observed that tGLI1, but not GLI1, significantly binds to the human VEGF-A gene promoter. To determine whether tGLI1 and GLI1 differ in their ability to transactivate the VEGF-A promoter, we engineered a luciferase reporter construct that is under the transcriptional control of the human VEGF-A gene promoter and a TATAA Box (top panel in Figure 3c ). Using this reporter construct, transfections and luciferase assay, we found that the VEGF-A gene promoter activity is significantly higher in tGLI1carrying MDA-MB-231 cells than in the isogenic control and GLI1-expressing cells (lower panel in Figure 3c ). Collectively, these results indicate that tGLI1 has gained the ability to upregulate VEGF-A gene expression. Figure 2 tGLI1 is associated with increased VEGF-A gene expression in human breast cancer and medulloblastoma cells. (a) Isogenic MDA-MB-231-GLI1 and MDA-MB-231-tGLI1 cell lines express GLI1 and tGLI1, respectively, at levels similar to those in natural breast cancer cells. The encoded tGLI1 protein (146 kD) was distinguished from the GLI1 protein (150 kD) using prolonged 5.5% SDS-PAGE followed by WB with an antibody that recognizes both GLI1 and tGLI1 isoforms. Top, WB. Bottom, RT-PCR. (b) VEGF-A gene is expressed at a higher level in tGLI1-expressing MDA-MB-231 cells than those with control vector and GLI1. Top, RT-PCR. Bottom, WB. (c) Expression of VEGF-A in breast cancer and medulloblastoma cells transiently transfected to express GLI1 or tGLI1, as shown by RT-PCR. (d) Human breast cancer cell lines with low tGLI1 levels expressed lower levels of VEGF-A than those with high levels of tGLI1, in which levels of tGLI1 were determined previously in Figure 1b . WB was conducted. tGLI1 upregulates VEGF-A and CD24 expression X Cao et al
Notably, we provide evidence to indicate that the human VEGF-A gene is a novel transcriptional target of the tGLI1 transcription factor.
tGLI1-expressing breast cancer cells secret high levels of VEGF-A and promote in vitro angiogenesis of human vascular endothelial cells
To determine whether tGLI1-expressing MDA-MB-231 cells secret more VEGF-A than the control and GLI1carrying isogenic cells, we conducted enzyme-linked immunosorbent assay (ELISA) to measure VEGF-A concentrations in the culture medium. As shown in Figure 4a , MDA-MB-231-tGLI1 cells secret higher levels of VEGF-A compared to MDA-MB-231-vector and MDA-MB-231-GLI1 cells. Consistent with this observation, conditioned medium from cultured MDA-MB-231-tGLI1 cells strongly promotes the ability of human umbilical vein endothelial cells (HUVECs) to form capillary-like structure that mimics in vivo angiogenesis ( Figure 4b ). We then quantified in vitro angiogenesis by measuring total tubule length (Figure 4c , left panel) and the number of branch points (right panel).
And the results indicate that the tGLI1-expressing MDA-MB-231 cells had a higher propensity to promote in vitro angiogenesis of HUVEC cells compared to their isogenic counterparts. As VEGF-A primarily binds to vascular endothelial growth factor receptor (VEGFR)-1/2, we determined the levels of all VEGFRs in HUVEC cells and found that these cells only express VEGFR-1/2 but not VEGFR-3 ( Supplementary Figure 1) . These results show, for the first time, that tGLI1 enhances VEGF-A secretion of breast cancer cells, leading to an enhancement of in vitro angiogenesis of human vascular endothelial cells.
tGLI1 significantly enhances breast cancer cell invasion and motility, independent of proliferation
In light of the ability of tGLI1 to promote glioblastoma cells migration and invasion (Lo et al., 2009) , we investigated whether this gain-of-function property of tGLI1 can be observed in breast cancer cells. This avenue is important because of the facts that increased motility and invasiveness are the major characteristics of metastatic breast cancer and that metastasis is the leading cause of breast cancer mortality. Using the scratch-wound assay that measures cell motility (Figure 5a ), we found that MDA-MB-231-tGLI1 cells are significantly more migratory than MDA-MB-231vector and MDA-MB-231-GLI1 cells. Increased migration is indicated by the high migration index (Im) derived from MDA-MB-231-tGLI1 cells. Next, we determined whether tGLI1 expression alters the proliferation rate of MDA-MB-231 cells and found that both tGLI1 and GLI1 increase cell proliferation after 48 h in culture ( Figure 5b ). However, the tGLI1-and GLI1-expressing MDA-MB-231 cells showed similar growth rate. Since the scratch-wound assay was conducted for 48 h, the tGLI1-mediated increase in migration occurred independent of cell proliferation. Furthermore, we conducted the invasion transwell assay that measures the ability of tumor cells to invade through basement membrane extracts over 48 h (Figures 5c and d) or 18 h ( Supplementary Figure 2 ). And the staining results indicate that MDA-MB-231-tGLI1 cells are more invasive than the isogenic counterparts. Following normalization against cell proliferation rates, the quantitative invasion assay (Figure 5d ) showed the net invasiveness (invasion:proliferation) of MDA-MB-231-tGLI1 cells to be B4-fold higher than those of MDA-MB-231-vector and MDA-MB-231-GLI1 cells. Together, these results indicate that tGLI1 has acquired the ability to substantially promote the propensity of human breast cancer cells to migrate and invade, independent of proliferation. Figure 3 tGLI1 has gained the ability to bind to and activate the human VEGF-A gene promoter. (a, b) tGLI1, but not GLI1, binds to the human VEGF-A gene promoter. Regular (a) and quantitative (b) ChIP assays were used to determine the extent to which tGLI1 and GLI1 bind to the human VEGF-A gene promoter. In these assays, IgG was used in immunoprecipitation as the negative control for GLI1/tGLI1 antibody, whereas chromatin inputs were used in PCR as the loading controls. The results were derived from three independent experiments and analyzed via the Student's t-test to determine P-values. (c) tGLI1, but not GLI1, transactivates the human VEGF-A gene promoter. The structure of the human VEGF-A promoter-containing luciferase reporter is shown in the top panel. The VEGF-A gene promoter reporter was co-transfected with the control pRL-CMV Renilla luciferase reporter into the isogenic MDA-MB-231 cells. Luciferase activity was measured 48 h after transfections. Relative promoter activity was computed by normalizing the Firefly luciferase activity against that of the Renilla luciferase. The VEGF-A gene promoter activity is significantly higher in tGLI1carrying MDA-MB-231 cells than the isogenic control and GLI1expressing cells. The results represent those from three independent experiments and were analyzed via the Student's t-test to derive Pvalues. A full colour version of this figure is available at the Oncogene journal online.
tGLI1 upregulates VEGF-A and CD24 expression X Cao et al tGLI1 is associated with increased expression of CD24, MMP-2 and MMP-9
To determine the molecular mechanisms underlying tGLI1-mediated breast cancer motility and invasion, we examined the effects of tGLI1 (and GLI1) on expression of three genes known to promote tumor invasion, migration and/or metastasis, namely, CD24, CD147 and heparanase. CD24 is a mucin-type glycoprotein and a ligand for a Ca 2 þ -dependent endogenous lectin, P-selectin (Aigner et al., 1997) that recruits adhesion molecules to lipid rafts and promotes cell migration, invasion and metastasis (Kristiansen et al., 2003; Baumann et al., 2005; Runz et al., 2008) . CD24 is overexpressed in breast cancer and associated with metastasis and shortened patient survival (Kristiansen et al., 2003; Lee et al., 2009 ). Accumulation of lactate within tumors has been correlated with poor clinical outcomes. CD147 is a chaperone to some monocarboxylate transporters that influence substrate availability, the metabolic path of lactate and pH balance within the tumor, thereby contributing to tumor progression and metastasis (Kennedy and Dewhirst, 2010) . Heparanase is a multi-functional protein that (i) cleaves heparan sulfate chains of extracellular matrix proteins, leading to disruption of basement membrane structure and subsequent migration of endothelial cells to tumors, (ii) releases heparan sulfate-bound angiogenic factors basic fibroblast growth factor and VEGF and (iii) generates heparan sulfate that enhances basic fibroblast growth factor:fibroblast factor growth factor receptor binding (Vlodavsky et al., 2002; Vreys and David, 2007) . Via gene expression profiling, we previously identified the human CD24 gene to be upregulated in tGLI1expressing glioblastoma cells (Lo et al., 2009 ). Using isogenic MDA-MB-231 cells, we found that CD24 gene expression is upregulated in MDA-MB-231-tGLI1 cells compared to those in MDA-MB-231-vector and MDA-MB-231-GLI1 cells (Figure 6a, left panel) . In contrast, (Figure 6c ). In contrast, both tGLI1 and GLI1 activate the 8 Â 3 0 Gli-BS luciferase reporter that is under the transcriptional control of eight copies of the consensus GLI1binding element (Figure 6d ). Next, we asked whether mouse mammary carcinoma cells expressed endogenous tGLI1 and whether transient expression of human tGLI1 activates mouse CD24 gene. The results in Figure 6e indicate that 4T1 mouse mammary carcinoma cells expressed endogenous mouse tGLI1; however, the human tGLI1 does not elevate mouse CD24 gene expression. Similarly, human tGLI1 does not upregulate mouse VEGF-A gene expression. These results suggest that human tGLI1 may not regulate mouse genes in the same manner as its human target genes. Furthermore, we found that MMP-2 is upregulated by tGLI1 in three of the four breast cancer cell lines we Luciferase activity was measured 48 h after transfections. Relative promoter activity was determined following normalizing the Firefly luciferase activity against that of the Renilla luciferase. The results were derived from three independent experiments and were analyzed by the Student's t-test to compute P-values. (d) Both tGLI1 and GLI1 activate the wild-type GLI1-targeted promoter. The 8 Â 3 0 Gli-BS luciferase reporter that is under the transcriptional control of eight copies of the consensus GLI1-binding element was cotransfected with the pRL-CMV Renilla luciferase reporter into the three isogenic MDA-MB-231 cell lines. Luciferase activity was determined 48 h post transfections. Relative promoter activity was computed by normalizing the Firefly luciferase activity against that of the Renilla luciferase. The results were derived from three independent experiments. The Student's t-test was performed to compute P-values. (e) Endogenous tGLI1 can be detected in 4T1 mouse mammary carcinoma cells. 4T1 cells were transiently transfected with control vector and human GLI1-and tGLI1-carrying expression vectors. After 48 h, RT-PCR was conducted to detect both human and mouse tGLI1 transcripts, and those of mouse CD24 and mouse VEGF-A genes. Notably, endogenous mouse tGLI1 was readily expressed in 4T1 cells. In contrast to the results from human breast cancer cells, human tGLI1 does not affect mouse CD24 and mouse VEGF-A expression in the cells, suggesting that human tGLI1 may not regulate mouse genes in the same manner as its target genes of the human origin. (f) MMP-2 was upregulated by tGLI1 in three of the four breast cancer cell lines we had analyzed, while MMP-9 was increased by tGLI1 in all four cell lines. Noticeably, MMP-2 expression in MCF-7 cells was not altered by tGLI1 or GLI1, while in HCC38 cells both tGLI1 and GLI1 upregulate MMP-2 expression.
tGLI1 upregulates VEGF-A and CD24 expression X Cao et al had analyzed and that MMP-9 level was increased by tGLI1 in all four cell lines (Figure 6f ). Both MMP-2 and MMP-9 are important factors that promote cancer invasion (Gondi et al., 2004; Ahmad et al., 2010) . Noticeably, MMP-2 expression in MCF-7 cells was not altered by tGLI1 or GLI1, while in HCC38 cells both tGLI1 and GLI1 upregulate MMP-2 expression. These observations indicate that the regulation of MMP-2 by tGLI1 and GLI1 is complex and likely to be dependent on cellular context. Collectively, results of Figure 6 indicate that tGLI1 is associated with increased expression of CD24, MMP-2 and MMP-9 genes, and that it has retained the capability to activate a wild-type GLI1targeted promoter.
tGLI1 enhances anchorage-independent growth of breast cancer cells In light of the association of the Hedgehog pathway with tumorigenesis, we next investigated whether tGLI1 alters breast cancer anchorage-independent growth, a property that partially mimics tumorigenesis. Using colony formation assays in the absence (Figure 7a ) and presence (Figure 7b ) of soft agar, we found that sub-populations of the MDA-MB-231-tGLI1 cells (about 3-5%) formed more and bigger colonies in both assays, compared to control cells and those with GLI1. Notably, tGLI1-expressing MDA-MB-231 cells produced colonies in a dose-dependent manner, 10-14 days after initial seeding (Figure 7a ). In the presence of soft agar (Figure 7b, left panel) , MDA-MB-231-tGLI1 cells produced visible large colonies B6 weeks after initial seeding. In the right panels of Figure 7b , we show three representative high-resolution ( Â 20) images from three different microscopic fields, in which MDA-MB-231-tGLI1 cells clearly formed larger colonies than the isogenic counterparts.
Discussion
We reported the discovery of the novel tGLI1 isoform and characterized its functionality in glioblastoma in our 2009 study (Lo et al., 2009 ). In this current study, we further addressed the importance of tGLI1 in breast cancer, in particular, in the more aggressive phenotypes of breast cancer. The results of this study indicate that tGLI1 has the ability to enhance the expression of four cancer-associated genes, VEGF-A, CD24, MMP-2 and MMP-9 in some breast cancer cell lines, and to promote several pathological processes in breast cancer cells, including in vitro angiogenesis, migration and invasion, and anchorage-independent growth. Our results also establish the human VEGF-A gene as a novel transcriptional target of the tGLI1 transcription factor. These observations collectively implicate tGLI1 in breast cancer growth and progression.
Using MDA-MB-231 cells, we found tGLI1 to be a stronger promoter of in vitro angiogenesis than GLI1. These findings are in line with previous studies showing that shh ligand increases vascularity (Kusano et al., 2005; Nagase et al., 2008) and our results demonstrating that shh can activate tGLI1 transcriptional activity (Figure 6d ). However, our results also suggest that tGLI1-mediated transcriptional regulation of VEGF-A may be dependent on cellular context. In this regard, tGLI1 may interact with other transcription factor(s) to co-regulate gene expression. This speculation also applies to the regulation of MMP-2 by tGLI1. Together, these observations call for a need to gain a deeper understanding of the mechanisms underlying tGLI1versus GLI1-mediated gene regulation.
Several important future tasks are prompted by our novel finding that tGLI1 enables sub-populations of MDA-MB-231 cells to undergo robust anchorageindependent growth. First, a new line of investigations will be necessary to explore if tGLI1 is associated with breast cancer stemness given that anchorageindependent growth is one of the unique features of cancer stem cells (Charafe-Jauffret et al., 2009). Second, it will be essential to investigate whether tGLI1 promotes tumorigenesis and metastasis as breast cancer stem cells have a high potential to initiate tumors and to metastasize (Liu and Wicha, 2010) . Third, it will also be an important task to gain further insights into the molecular mechanisms by which tGLI1 mediates the anchorage-independent growth of MDA-MB-231 cells. In light of our data showing the ability of tGLI1 to enhance VEGF-A expression and previous reports indicating that MDA-MB-231 cells express high levels of VEGFR-1 (Schmidt et al., 2008) , it is possible that the VEGF-A-VEGFR-1 autocrine effect contributes to their growth under a non-adherent growth condition. The possibility should be addressed by future work.
Our results indicate that CD24 is a transcriptional target of tGLI1, but not of GLI1, in breast cancer. This finding is in agreement with our previous study that showed similar results in glioblastoma models using a combination of DNA microarray and subsequent biochemical validations (Lo et al., 2009) . Using glioblastoma models, we also showed that transcriptional knockdown of CD24 significantly reduced tGLI1mediated tumor cell migration and invasion in a proliferation-independent manner. In line with our observations, CD24 has been shown to be involved in cancer cell motility, invasion and metastasis (Kristiansen et al., 2003; Baumann et al., 2005; Runz et al., 2008) and shortened patient survival (Kristiansen et al., 2003; Lee et al., 2009) . Also consistent with these reports are the facts that CD24 recruits adhesion molecules to lipid rafts (Runz et al., 2008) and that CD24 indirectly stimulates cell adhesion to fibronectin, collagens I/IV and laminin through the activation of integrins (Baumann et al., 2005) . Interestingly, several studies have shown that some breast cancer-initiating stem cells display the characteristic of being low or negative for CD24 expression but high for CD44 (Al-Hajj et al., 2003; Kim et al., 2007) . This notion is not in agreement with our results showing that tGLI1 expression enables MDA-MB-231 cells to grow in an anchorage-independent manner, a property commonly displayed by cancer tGLI1 upregulates VEGF-A and CD24 expression X Cao et al stem cells. However, in support of our results, a recent report showed that CD24 expression does not define breast cancer stem cells (Meyer et al., 2010) . Also in agreement with our results, another recent study reported that pancreatic cancer stem cells demonstrate the CD44 þ CD24 þ ESA þ phenotype (Li et al., 2007) . It has been suggested that the role of CD24 in cancer stemness may be tissue specific (Keysar and Jimeno, 2010) . Clearly, more work is needed to define the role that CD24 plays in both cancer progression and stem cell biology.
Materials and methods
Reagents, cell lines and primary specimens All chemicals were purchased from Sigma (St Louis, MO, USA) unless otherwise stated. Human breast cancer cell lines 
RT-PCR
Total RNA isolation and RT were conducted using SV Total RNA Isolation System (Promega, Madison, WI, USA) and Superscript II First-Strand cDNA synthesis system (Invitrogen, Carlsbad, CA, USA), retrospectively. The forward and reverse primers used for the PCR were 5 0 -TGTTCAACTC GATGACCC-3 0 and 5 0 -GTCATGGGGACCACAAGG-3 0 (exons 1-4 of GLI1 and tGLI1); 5 0 -GGCGGCACCACCA TGTACCC-3 0 and 5 0 -AGGGGCCGGA CTCGTCATACT-3 0 (b-actin); 5 0 -ATGGGCAGAGCAATGGTGGCCA-3 0 and 5 0 -AGAGTGAGACC ACGAAGAGACT-3 0 (human CD24); 5 0 -ATGGGCAGAGCGATGGTGGCCA-3 0 and 5 0 -AGAAG AG AGAGAGAGAGAGCCA-3 0 (mouse CD24); 5 0 -CACCA TCGACAGAACAGTCC-3 0 and 5 0 -GAATCC AATTCCAA GAGGGA-3 0 (human VEGF-A); 5 0 -ATGAACTTTCTGCTC TCTTGGGT-3 0 and 5 0 -ACA CAGGACGGCTTGAAGATG TA-3 0 (mouse VEGF-A); 5 0 -ACAGTCTTCACTACCGTA GA-3 0 and 5 0 -TTCTGACGACTTCACAGCCT-3 0 (CD147); 5 0 -GGTCAGCCTCGAAGAAAGAC-3 0 and 5 0 -TAGCAGT CCGTCCATTCAAA-3 0 (heparanase); 5 0 -AGATCTTCTTCT TCAAGGACCGGTT-3 0 and 5 0 -GGCTGG TCAGTGGCTT GGGGTA-3 0 (MMP-2); and 5 0 -CTGCCAGTTTCCATTCAT CT-3 0 and 5 0 -GTCAAAGTT CGAGGTGGTAG-3 0 (MMP-9).
Western blotting
This was performed as described previously (Lo et al., 2008a, b) . Antibodies used included mouse monoclonal antibodies against b-actin (Sigma) and a-tubulin (Sigma); and rabbit polyclonal antibodies for VEGF-A (Santa Cruz, Santa Cruz, CA, USA; sc-152), GLI1 (Santa Cruz; H300) and CD24 (Santa Cruz; FL-80); and goat polyclonal GLI1 antibody (Santa Cruz; C-18).
ChIP assay to determine binding of tGLI1 to the VEGF-A gene promoter
This was performed using a ChIP Assay Kit (Upstate, Billerica, MA, USA) as we described previously (Lo et al., 2005) . A rabbit polyclonal GLI1 antibody (Santa Cruz; H300) that recognizes the COOH-terminal region (aa 781-1080) present in both GLI1 and tGLI1 proteins was used in these experiments. DNA sequences for the primers used to amplify the VEGF-A promoter are 5 0 -GCACATTGTCAGAGGGACAC-3 0 (forward) and 5 0 -CCCTATTTCTGACCTCCCAA-3 0 (reverse).
Plasmids, transfection and luciferase assay
Construction of the GLI1-and tGLI1-expressing plasmids was described in our previous study (Lo et al., 2009 ). The GLI1binding sites-driven luciferase construct, 8 Â 3 0 Gli-BS Luc, was generously provided by Dr Hiroshi Sasaki at Osaka University, Japan (Sasaki et al., 1997) . The reporter construct pCD24-0.25kb-Luc was engineered in our previous study (Lo et al., 2009 ). To generate the pGL3-VEGF-A-Luc reporter, the promoter region of the human VEGF-A (À900 to þ 100 bp) was cloned into the pGL3-basic Firefly luciferase vector (Promega). All transfections were performed with cells in exponential growth using lipofectamine 2000 (Invitrogen) and FuGENE HD (Roche, Indianapolis, IN, USA). A Renilla luciferase expression vector, pRL-CMV, was used to control for transfection efficiency. Forty-eight hours after transfection, the cells were lysed and luciferase activity was measured using the Firefly and Renilla Luciferase Assay Kit (Biotium, Hayward, CA, USA), as we previously described (Lo et al., 2005 (Lo et al., , 2007 (Lo et al., , 2008a . Relative promoter activity was computed by normalizing the Firefly luciferase activity against that of the Renilla luciferase.
ELISA that measures VEGF-A concentrations in culture medium
This was conducted using the VEGF-A ELISA Kit from R&D (Minneapolis, MN, USA), according to the manufacturer's instructions. Breast cancer cells seeded in 24-well culture plates were incubated in the EBM-2 Basal Medium (LONZA) at 37 1C. After 24 h, conditioned medium was collected and centrifuged at 1200 g for 10 min to remove cell debris. The supernatants were then subjected to ELISA in triplicates. Absorbance at 540 nm (and 450 nm as normalization background) was determined using the Synergy HT Multi-mode Microplate Reader (BioTek, Winooski, VT, USA). VEGF-A concentrations were computed with reference to standard curves derived from purified VEGF-A supplied in the ELISA Kit.
Tubule formation assay that measures in vitro angiogenesis of vascular endothelial cells Tubule formation assay was performed using the in vitro Angiogenesis Kit from Trevigen (Gaithersburg, MD, USA). Briefly, 96-well culture plates were coated with 50 ml Cultrex Basement Membrane Extracts (Trevigen) per well and incubated at 37 1C for 1 h or until the gel has solidified. A total of 5000 HUVEC cells were then seeded in each coated well and incubated with EBM-2 Basal Medium (LONZA) with and without supplementation of growth factor (EGM-2 BulletKit; LONZA) or with tumor conditioned medium. Conditioned medium was collected from stable MDA-MB-231 cells that have been starved in EBM-2 Basal Medium for 24 h. After incubation at 37 1C for 4-6 h, HUVEC cells were examined for capillary-like network formation and photographed under a light microscope. Images were taken from 3 to 5 different fields in each well. Tubule formation was quantified by measuring total tubule length and total number of branch points in triplicate wells, using the NIH Image J software according to a published protocol (Dasari et al., 2010) .
Scratch-wound assay that determines cell migration Breast cancer cells seeded in 6-well culture plates were scratched via a pipette tip to create a gap, incubated at 37 1C and imaged every 2 h using a digital camera attached to a Carl Zeiss microscopy. Gap width was determined from the images taken using AXIO 4.0 software (Carl Zeiss, Thornwood, NY, USA). For each gap, the average width was computed from three measurements taken at the top, middle and bottom end of the microscopic field. The migratory index, Im, was computed via the equation: Im ¼ (g 0 Àg t )/g 0 (g 0 ¼ gap width at time zero; g t ¼ gap width at time t).
Cell proliferation assay
This was performed, as we described previously (Lo et al., 2008a; Cao et al., 2011) , using the CellTiter Blue Cell Viability Assay kit (Promega), a fluorescent method that is based on the tGLI1 upregulates VEGF-A and CD24 expression X Cao et al ability of living cells to convert a redox dye (resazurin) into a fluorescent end product (resorufin). Briefly, the cells were seeded in 96-well cell-culture plates (4 Â 10 3 per well) and at 0, 24, 48 and 72 h, the degrees of cell viability were determined.
Invasion assay
This was conducted as we previously described using the InnoCyte Quantitative Cell Invasion Assay kit (EMD, Darmstadt, Germany) (Lo et al., 2009) . Briefly, 1.75 Â 10 5 cells were placed in the upper chamber of re-hydrated inserts with an 8-mm pore size polycarbonate membrane coated with a uniform layer of basement membrane matrix on the upper surface. Following incubation for 48 h, the medium in the upper chamber was discarded and the inserts placed in fresh wells containing fluorescent Calcein-AM cell staining/detachment buffer. Aliquots of the fluorescence-stained dislodged cells were transferred to duplicate wells of a 96-well cell-culture plate and the fluorescence was measured. The inserts containing the breast cancer cells invaded through the basement membrane matrix were stained in 0.5% crystal violet. Cell proliferation rates were simultaneously determined (Lo et al., 2008a (Lo et al., , 2009 to derive 'invasiveness:proliferation' ratios that indicate net invasiveness.
Determination of anchorage-independent growth by the colony formation assays Clonogenic growth assays were performed in 6-well cellculture plates with 500, 1000 and 2000 cells per well, as we previously described (Lo et al., 2005 . For the experi-ments with soft agar, 1000 cells were seeded in each well and all wells were pre-coated with 0.5% agarose as the bottom layer whereas the top layer is consisted of 0.3% agarose and tumor cells. Following 10-14 days (without soft agar) and 6 weeks (with soft agar), colonies were stained with crystal violet blue solution (Sigma) for 1 h and counted under a microscope. Triplicate wells were used for each cell line and three independent experiments were performed.
